New AI Tool Enhances Precision of Lung Cancer Radiation Therapy
“A new artificial intelligence tool developed by researchers at Northwestern Medicine has matched expert physicians in mapping lung tumors for radiation therapy and may even improve on their accuracy by identifying tumor regions some doctors miss. The study detailing this tool, called iSeg, was published NPJ Precision Oncology.”
Colorado Researcher Receives Department of Defense Grant for 3D Lung Cancer Modeling System
“A three-dimensional model of lung tissue developed by University of Colorado Cancer Center member Chelsea Magin, PhD, will help the U.S. military better research, treat and prevent lung cancer. “Military service members are more likely to develop lung cancer than the general population due to a combination of occupational exposures and lifestyle factors,” Magin explains. “Many veterans were exposed to hazardous substances, such as particulate matter from burn pits or diesel exhaust, during military service. Additionally, smoking rates among veterans are approximately twice as high as the general population. Due to these factors, nearly 1 million veterans remain at high risk for lung cancer.””
Exposure to Cooking Fumes Linked to Increased Risk for Lung Cancer in Never Smokers
“A systematic review found that higher lifetime exposure to cooking oil fumes was associated with an increased risk for lung cancer in never-smoking women in high-income countries.”
Decline in SCLC Incidence Expected to Accelerate Through 2050
“Key Takeaways: SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study used SEER 17 data, showing a steady decline in SCLC cases across demographics, attributed to reduced tobacco use.”
TROP2-directed Antibody-drug Conjugate Approved for EGFR-Mutated Lung Cancer
“The U.S. Food and Drug Administration (FDA) has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbors EGFR mutations and has previously been treated with EGFR-directed therapy and chemotherapy.”
Study points to promising chemoimmunotherapy strategy for aggressive stage III non-small cell lung cancer
“A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery for patients with aggressive stage III non-small cell lung cancer that is considered difficult or impossible to surgically remove can help shrink tumors and make surgery possible.”
Frontline Firmonertinib Generates Durable Efficacy in EGFR PACC–Mutant NSCLC
“Key Takeaways: Firmonertinib at 240 mg showed a median PFS of 16.0 months and an ORR of 68.2% in EGFR PACC–mutant NSCLC patients. The CNS ORR was 53%, with a 41% complete response rate, indicating significant CNS activity.”
Depression in Lung Cancer Tied to Inflammation Risk
“For the first time, researchers have found that lung cancer patients who have a combination of high levels of depression and inflammation at diagnosis are later found with continuing depressive symptoms in the next several months, even as they receive new, promising therapies.”
Anlotinib Following Benmelstobart Plus Chemotherapy Improves Progression-Free Survival in S-NSCLC
“Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. The data, presented at the 2025 American Society of Clinical oncology Annual Meeting, suggest the regimen as a new first-line treatment for patients with squamous non-small cell lung cancer (s-NSCLC).”
NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC
“Key Takeaways: Taletrectinib is now a preferred treatment for advanced ROS1-positive NSCLC, including brain metastases and resistance mutations, per updated NCCN guidelines. FDA approval of taletrectinib was based on phase 2 TRUST-I and TRUST-II trials, showing high response rates and durable responses.”
